WallStreetZenWallStreetZen

NASDAQ: CGEM
Cullinan Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CGEM

Based on 3 analysts offering 12 month price targets for Cullinan Therapeutics Inc.
Min Forecast
$29.00+62.19%
Avg Forecast
$29.67+65.92%
Max Forecast
$30.00+67.79%

Should I buy or sell CGEM stock?

Based on 3 analysts offering ratings for Cullinan Therapeutics Inc.
Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CGEM stock forecasts and price targets.

CGEM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-17
lockedlocked$00.00+00.00%2024-04-16
lockedlocked$00.00+00.00%2024-02-15

1 of 1

Forecast return on equity

Is CGEM forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.72%

Forecast return on assets

Is CGEM forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CGEM revenue forecast

What is CGEM's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$10.8M
Avg 2 year Forecast
$44.8M
Avg 3 year Forecast
$56.6M

CGEM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CGEM$17.88$29.67+65.92%Strong Buy
CRGX$19.50$29.67+52.14%Strong Buy
PLRX$12.86$46.67+262.88%Buy
TYRA$14.45$25.50+76.47%Buy
RGNX$17.03$40.38+137.08%Strong Buy
View Top Biotech Stocks

Cullinan Therapeutics Stock Forecast FAQ

Is Cullinan Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: CGEM) stock is to Strong Buy CGEM stock.

Out of 3 analysts, 1 (33.33%) are recommending CGEM as a Strong Buy, 2 (66.67%) are recommending CGEM as a Buy, 0 (0%) are recommending CGEM as a Hold, 0 (0%) are recommending CGEM as a Sell, and 0 (0%) are recommending CGEM as a Strong Sell.

If you're new to stock investing, here's how to buy Cullinan Therapeutics stock.

What is CGEM's revenue growth forecast for 2024-2026?

(NASDAQ: CGEM) Cullinan Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.27%.

Cullinan Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CGEM's revenue for 2024 to be $466,659,329, with the lowest CGEM revenue forecast at $466,659,329, and the highest CGEM revenue forecast at $466,659,329. On average, 2 Wall Street analysts forecast CGEM's revenue for 2025 to be $1,929,556,224, with the lowest CGEM revenue forecast at $1,804,493,591, and the highest CGEM revenue forecast at $2,054,661,923.

In 2026, CGEM is forecast to generate $2,439,453,461 in revenue, with the lowest revenue forecast at $2,235,106,976 and the highest revenue forecast at $2,643,799,947.

What is CGEM's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CGEM) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CGEM's Price Target?

According to 3 Wall Street analysts that have issued a 1 year CGEM price target, the average CGEM price target is $29.67, with the highest CGEM stock price forecast at $30.00 and the lowest CGEM stock price forecast at $29.00.

On average, Wall Street analysts predict that Cullinan Therapeutics's share price could reach $29.67 by Apr 17, 2025. The average Cullinan Therapeutics stock price prediction forecasts a potential upside of 65.92% from the current CGEM share price of $17.88.

What is CGEM's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CGEM) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.